HIGH SPECIFIC ACTIVITY PREPARATION OF F-18 TETRAFLUOROBORATE

Abstract

Embodiments of the invention provide methods of synthesizing .sup.18F-tetrafluoroborate (.sup.18F-TFB) via direct radiofluorination on boron trifluoride (BF.sub.3) to enhance both labeling yield and specific activity. Uses of .sup.18F-TFB are also contemplated.

Claims

1. A method of radiolabeling tetrafluoroborate (TFB) with .sup.18F-fluoride, the method comprising direct radiofluorination on boron trifluoride (BF.sub.3) by reacting the BF.sub.3 directly with .sup.18F-fluoride.

2. A method of radiolabeling tetrafluoroborate with .sup.18F-fluoride, the method comprising: (a) reacting .sup.18F-fluoride with BF.sub.3; and (b) isolating the .sup.18F-TFB from unreacted .sup.18F-fluoride and BF.sub.3.

3. The method of claim 2, wherein the .sup.18F-fluoride is trapped on an anion exchange cartridge and the reacting of step (a) of .sup.18F-fluoride with BF.sub.3 is performed on the anion exchange cartridge.

4. The method of claim 3, wherein the anion exchange cartridge is a quaternary methyl ammonium anion exchange (QMA) cartridge.

5. The method of any one of claims 2, 3 or 4, wherein the BF.sub.3 in step (a) was provided in a solution of BF.sub.3.THF complex in petroleum ether.

6. The method of claim 5, wherein BF.sub.3.THF complex was filtered to remove BF.sub.4-before reacting with .sup.18F-fluoride.

7. The method of any one of claims 3-6, wherein the cartridge is washed after step (a) to remove unreacted BF.sub.3 and residual solvent.

8. The method of any one of claims 2-7, wherein the .sup.18F-fluoride is prepared before step (a) by irradiation of .sup.18O-water.

9. The method of any one of claims 3-8, wherein step (b) comprises eluting .sup.18F-TFB product from the anion exchange cartridge.

10. The method of claim 9, wherein .sup.18F-TFB is eluted from the anion exchange column using saline.

11. The method of any one of claims 2-10, wherein the crude .sup.18F-TFB product solution was further purified from unreacted .sup.18F-fluoride by passing through a cartridge comprising alumina with a neutral surface chemistry.

12. The method of any one of the preceding claims, wherein the .sup.18F-TFB has a specific activity of at least 5 GBq/μmol.

13. The method of any one of the preceding claims, wherein the .sup.18F-TFB has a specific activity of at least 8 GBq/μmol.

14. The method of any one of the preceding claims, wherein the .sup.18F-TFB was synthesized in radiochemical yield of 15% with greater than 90% purity.

15. The method of any one of the preceding claims, wherein the .sup.18F-TFB was synthesized in radiochemical yield of 20% with greater than 90% purity.

16. The method of any one of the preceding claims, wherein the .sup.18F-TFB was synthesized in radiochemical yield of at least 25%.

17. The method of any one of the preceding claims, wherein the .sup.18F-TFB was synthesized in radiochemical yield of at least 30%.

18. The method of any one of the preceding claims, wherein the .sup.18F-TFB was has a purity of at least 95%

19. The method of any one of the preceding claims, wherein the .sup.18F-TFB was synthesized in radiochemical yield of at least 30%.

20. A method of radiolabeling tetrafluoroborate with .sup.18F-fluoride, the method consisting essentially of: (a) trapping .sup.18F-fluoride on an anion exchange column; (b) reacting .sup.18F-fluoride with BF.sub.3; and (b) isolating the .sup.18F-TFB from unreacted .sup.18F-fluoride and BF.sub.3 from the anion exchange column, wherein the resultant .sup.18F-TFB has a specific activity of at least 5 GBq/μmol.

21. The method of claim 20, wherein the BF.sub.3 in step (a) was provided in a solution of BF.sub.3.THF complex in petroleum ether.

22. The method of claim 21, wherein BF.sub.3.THF complex was filtered to remove BF.sub.4— before reacting with .sup.18F-fluoride.

23. The method of any one of claims 20-22, wherein the column is washed after step (a) to remove unreacted BF.sub.3 and residual solvent from the column.

24. The method of any one of claims 20-23, wherein the .sup.18F-TFB has a specific activity of at least 8 GBq/μmol.

25. The method of any one of claims 20-24, wherein the .sup.18F-TFB was synthesized in radiochemical yield of 15% with greater than 95% radiochemical purity.

26. The method of any one of claims 20-25, wherein the .sup.18F-TFB was synthesized in radiochemical yield of 20% with greater than 95% radiochemical purity.

27. A high specific activity preparation of .sup.18F-tetrafluoroborate synthesized by any one of the methods of claims 1-26 with a at least 95% radiochemical purity.

28. The high specific activity preparation of .sup.18F-TFB of claim 27, wherein the specific activity is at least 8 GBq/μmol.

29. Use of the .sup.18F-tetrafluoroborate of claim 27 for imaging of thyroid or breast cancer.

30. Use of .sup.18F-tetrafluoroborate of claim 27 for imaging of thyroid, breast, stomach, salivary glands or kidney.

31. The use of claim 29 or 30, wherein the effective dose was about 0.036 mSv/MBq in males and about 0.064 mSv/MBq in females.

32. Use of the .sup.18F-tetrafluoroborate of claim 27 for monitoring gene therapies that employ the hNIS reporter gene.

Description

DESCRIPTION OF THE DRAWINGS

[0011] FIG. 1A is a schematic showing the preparation of BF.sub.3.THF/PE complex solution.

[0012] FIG. 1B is a schematic of an alternative simplified method of preparing BF.sub.3.THF/PE complex solution.

[0013] FIG. 2 is a depiction of the in-house-made Lewatit® MP-64 cartridge.

[0014] FIG. 3 is a schematic of automated module for the preparation of .sup.18F-TFB. Valves V1-V5 are composed of a single-use cassette that is mounted to the front of the module. All other valves are non-disposable Teflon diaphragm solenoid valves.

[0015] FIG. 4 depicts the relationship of radiochemical yields (uncorrected) to the amount of unlabeled BF.sub.4— produced as found using different amounts of MP-64 resin to pre-filter the BF.sub.3.THF/PE reagent (data from Table 1).

[0016] FIG. 5 is a graph showing radio-TLC of purified .sup.18F-TFB (Rf=0.8-0.85) with the silica gel stationary phase and methanol mobile phase. If present, unreacted .sup.18F-fluoride would remain at the origin.

[0017] FIG. 6A depicts HPLC analysis of the .sup.18F-TFB product in saline, conductivity data for 10 μg/mL NaF standard.

[0018] FIG. 6B depicts HPLC analysis of the .sup.18F-TFB product in saline, conductivity data for 10 μg/mL NaBF4 standard.

[0019] FIG. 6C depicts HPLC analysis of the .sup.18F-TFB product in saline, radioactivity data for 1.1 MBq .sup.18F-fluoride standard.

[0020] FIG. 6D depicts HPLC analysis of the .sup.18F-TFB product in saline, conductivity data for purified .sup.18F-TFB in saline,

[0021] FIG. 6E depicts HPLC analysis of the .sup.18F-TFB product in saline, radioactivity data for purified .sup.18F-TFB in saline.

[0022] FIG. 7 shows GC analysis of residual organic solvents in the final .sup.18F-TFB product. No obvious petroleum ether peaks were observed.

[0023] FIG. 8 is a schematic of the putative reaction scheme for formation of .sup.19F/.sup.18F-TFB from BF.sub.3 of the preparation of BF.sub.3.THF/PE complex solution.

[0024] FIG. 9A is a graph depicting time dependence of .sup.18F-TFB uptake (SUV) in different organs in representative hNIS-expressing C6 glioma xenografted mice at high specific activity of .sup.18F-TFB (13 MBq/μmol or 0.37 mg/kg mouse weight).

[0025] FIG. 9B is a graph depicting time dependence of .sup.18F-TFB uptake (SUV) in different organs in representative hNIS-expressing C6 glioma xenografted mice at low specific activity of .sup.18F-TFB (3 MBq/μmol or 1.6 mg/kg mouse weight).

[0026] FIG. 10 depicts PET images of .sup.18F-TFB distribution in control mouse (left) and a mouse bearing hNIS-positive and hNIS-negative C6 glioma xenografts (right). The overlaid reference bone atlas is computer generated.

[0027] FIG. 11A depicts dependence of tumor of .sup.18F-TFB uptake on administered mass of TFB to hNIS-expressing C6 glioma xenografted mice.

[0028] FIG. 11B depicts dependence of stomach of .sup.18F-TFB uptake on administered mass of TFB to hNIS-expressing C6 glioma xenografted mice.

[0029] FIG. 11C depicts dependence of tumor/stomach ratio of .sup.18F-TFB uptake on administered mass of TFB to hNIS-expressing C6 glioma xenografted mice. The tumor/stomach ratio data for administered mass >0.5 mg/kg was fit to a bi-exponential clearance model using non-linear least-squares regression. Microsoft Excel Solver was used to regress the tumor/stomach ratios using a nonlinear least-squares regression algorithm.

[0030] FIG. 12 are pictures representing immunostaining of hNIS-expressing C6 glioma xenografts (10× magnification) showing intra-tumoral and inter-tumoral variability of expression of hNIS. (Green: Alexa Fluor 488 antibody bound hNIS and Blue: DAPI stained nuclei)

[0031] FIG. 13 is a schematic representation of the imaging protocol. Patients were screened on day 1 and imaged by .sup.18F-TFB PET/CT on day 2.

[0032] FIG. 14 depicts a graph showing time-activity curves of .sup.18F-TFB in healthy mail participant. LVBP=left-ventricular blood pool.

[0033] FIG. 15A are coronal PET/CT images of .sup.18F-TFB in healthy male participants at 2 hour post-injection. Physiologic distribution of .sup.18F-TFB is seen in thyroid, salivary glands, stomach and intestines. Prominent excretion of radioactivity is seen in urinary bladder.

[0034] FIG. 15B are coronal PET/CT images of .sup.18F-TFB in healthy female participants at 2 hour post-injection. Physiologic distribution of .sup.18F-TFB is seen in thyroid, salivary glands, stomach and intestines. Prominent excretion of radioactivity is seen in urinary bladder.

DETAILED DESCRIPTION

[0035] Before any embodiments of the invention are explained in detail, it is to be understood that the invention is not limited in its application to the details of construction and the arrangement of components set forth in the following description or illustrated in the following drawings. The invention is capable of other embodiments and of being practiced or of being carried out in various ways. Also, it is to be understood that the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.

[0036] The following discussion is presented to enable a person skilled in the art to make and use embodiments of the invention. Various modifications to the illustrated embodiments will be readily apparent to those skilled in the art, and the generic principles herein can be applied to 7other embodiments and applications without departing from embodiments of the invention. Thus, embodiments of the invention are not intended to be limited to embodiments shown, but are to be accorded the widest scope consistent with the principles and features disclosed herein. The following detailed description is to be read with reference to the figures, in which like elements in different figures have like reference numerals. The figures, which are not necessarily to scale, depict selected embodiments and are not intended to limit the scope of embodiments of the invention. Skilled artisans will recognize the examples provided herein have many useful alternatives and fall within the scope of embodiments of the invention.

[0037] A method of radiolabeling tetrafluoroborate (TFB) with .sup.18F-fluoride is provided. The method comprises the direct radiofluorination on boron trifluoride (BF.sub.3) by reacting the BF.sub.3 directly with .sup.18F-fluoride. This method provides .sup.18F-TFB with an enhanced labeling yield and higher specific activity.

[0038] In some embodiments, the method comprises (a) reacting .sup.18F-fluoride with BF.sub.3; and (b) isolating the .sup.18F-TFB from unreacted .sup.18F-fluoride and BF.sub.3. In some embodiments, the .sup.18F-fluoride is trapped on an anion exchange cartridge or column and the reacting of step (a) of .sup.18F-fluoride with BF.sub.3 is performed on the anion exchange cartridge or column. In this method, the reacted .sup.18F-TFB remains on the anion exchange cartridge or column to be separated from the unreacted .sup.18F-fluoride and BF.sub.3.

[0039] Suitable anion exchange columns or cartridges are known in the art. For example, in some embodiments, the anion exchange cartridge is a quaternary methyl ammonium anion exchange (QMA) cartridge. Suitable anion exchange resins will have a sufficient affinity for .sup.18F-TFB as to be able to separate the .sup.18F-TFB from the unreacted .sup.18F-fluoride and BF.sub.3.

[0040] In some embodiments, the anion exchange cartridge or column containing the .sup.18F-TFB is washed at least once to remove the unreacted BF.sub.3 and residual solvent from the cartridge. The anion exchange cartridge or column may be washed with a suitable wash solution. Suitable wash solutions include, but not limited to, for example, THF and/or water to remove the unreacted BF.sub.3 and residual solvent. In some embodiments, the wash solution comprises ether. In some embodiments, the cartridge or column is washed at least one, at least twice, at least three times. In some embodiments, the column is first washed with THF and then washed with distilled water. In another embodiment, the column is washed sequentially with THF and water. In some embodiments, the column is washed with about 10 mL of THF followed by 10 mL of water.

[0041] The .sup.18F-TFB is eluted from the anion exchange column. In some embodiments, the .sup.18F-TFB is eluted using saline. In other embodiments, the .sup.18F-TFB is eluted with solution selected from the group consisting of phosphate buffer saline (PBS), sodium citrate, sodium chloride and sodium bicarbonate. Suitable concentrations of saline for removal of the .sup.18F-TFB are known in the art and include, but are not limited to, about 0.9% NaCl.

[0042] The eluted crude .sup.18F-TFB may be further purified by passing through a second column or cartridge comprising alumina with a neutral surface chemistry. Suitable columns or cartridges include, but are not limited to, for example, alumina-N SepPak Plus cartridge (SepPak®). The second column or cartridge is used to remove unreacted .sup.18F-fluoride from the solution. The eluted crude .sup.18F-TFB may be passed over at least one second column or cartridge. In some embodiments, the eluted crude .sup.18F-TFB may be passed over at least two second column or cartridges. In some embodiments, the eluted crude .sup.18F-TFB may be passed over at least three second column or cartridges. In some embodiments, the eluted .sup.18F-TFB is passage through a sterilizing filter. In some embodiments, the sterilizing filter is 0.2 μM.

[0043] For the methods provided herewith, BF.sub.3 may be provided in a solution of BF.sub.3.THF complex in petroleum ether. BF.sub.3.THF may be produced by methods known in the art, for example, from BF.sub.3 gas dissolved in THF using petroleum ether. In some instances, the BF.sub.3.THF complex was filtered to remove BF.sub.4— before reacting with .sup.18F-fluoride. In some embodiments, the BF.sub.3.THF complex was passed over a anion exchange resin, for example, an anion exchange resin that contains crosslinked polystyrene matrix with tertiary amine and quaternary ammonium functional groups (e.g. Lewatit® MP-64).

[0044] In other embodiments, the BF.sub.3 may be provided as, for example, BF.sub.3.pyridine, BF.sub.3.Et.sub.3N, BF.sub.3.MeOH, BF.sub.3.EtOH, BF.sub.3.Et.sub.2O and BF.sub.3.THF, among others. [The .sup.18F-fluoride may be prepared by known methods in the art, for example, by irradiation of .sup.18O-water. Suitable methods of irradiating .sup.18O-water are known in the art, and include, using 50-70 uA (e.g. 65 uA) for about 10-30 (e.g. 15) minutes in cyclotron.

[0045] In some embodiments, the .sup.18F-fluoride used has radioactivities of about 10 to about 50 MBq. In some embodiments, the .sup.18F-fluoride used has radioactivities of about 15 to about 37 MBq.

[0046] The disclosed methods provide purified .sup.18F-TFB with of specific activity of at least 5 GBq/μmol. In some instances, the methods provide .sup.18F-TFB with a specific activity of at least 8 GBq/μmol. In one embodiment, the purified .sup.18F-TFB has a specific activity of at least 8.8 GBq/μmol.

[0047] The disclosed methods synthesize .sup.18F-TFB with a radiochemical yield of at least 15% with greater than about 95% purity. In some embodiments, methods provide .sup.18F-TFB with a radiochemical yield of up to 40% with greater than about 95% purity. In some instances, the radiochemical yield is at least about 10%, at least about 20%, at least about 30%, at least about 40%.

[0048] The disclosure provides .sup.18F-TFB made by the methods provided. The .sup.18F-TFB is at least about 95% pure, in some embodiments, at least 98% pure. In some embodiments, the methods synthesize .sup.18F-TFB with at least about 95% purity. In some embodiments, the methods synthesize .sup.18F-TFB with about 98% purity. The .sup.18F-TFB provide has a specific activity of at least 3 GBq/μmol, alternatively at least 5 GBq/μmol, alternatively at least 8 GBq/μmol.

[0049] In some embodiments, a method of radiolabeling tetrafluoroborate with .sup.18F-fluoride consists essentially of: (a) trapping .sup.18F-fluoride on an anion exchange column; (b) reacting .sup.18F-fluoride with BF.sub.3; and (c) isolating the .sup.18F-TFB from unreacted .sup.18F-fluoride and BF.sub.3 from the anion exchange column, wherein the resultant .sup.18F-TFB has a specific activity of at least 5 GBq/μmol. In this method, the .sup.18F-TFB remains attached to the column or cartridge until eluted using an isotonic saline solution. The column or cartridge containing .sup.18F-TFB may be washed with at least one wash solution before eluting the .sup.18F-TFB. The method may further include purifying the .sup.18F-TFB by running over a column or cartridge comprising alumina with a neutral surface chemistry. Suitable columns or cartridges include, but are not limited to, for example, alumina-N SepPak® Plus cartridge (SepPak®). In some embodiments, the eluted .sup.18F-TFB is passage through a sterilizing filter.

[0050] This disclosure provides methods of synthesizing .sup.18F-TFB in less than 30 minutes, alternatively less than 20 minutes, alternatively less than 10 minutes. In one embodiment, the method of synthesizing .sup.18F-TFB is performed in about 10 minutes, in some instances in about 9 to 15 minutes. The following Examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and the following examples and fall within the scope of the appended claims.

EXAMPLES

Example 1: Synthesis of .SUP.18.F-Tetrafluoroborate (.SUP.18.F-TFB) Via Radiofluorination of Boron Trifluoride and Evaluation in Murine C6-Glioma Tumor Model

Materials and Methods

[0051] Lewatit® MP-64 chloride form resin was procured from Sigma Aldrich (St. Louis, Mo.) and preconditioned with 1 M K.sub.2CO.sub.3 solution (10 equivalent), water (100 equivalent, w/w) and tetrahydrofuran (THF) (100 equivalent, w/w) in a column, and then dried under nitrogen overnight. Acetone, THF and a BF.sub.3 gas cylinder were purchased from Sigma Aldrich. Petroleum ether was procured from Fisher Scientific. Sep-Pak Accell Plus QMA Carbonate Plus Light (46 mg sorbent per cartridge, 40 μm particle size), Alumina-N SepPak Plus cartridges and Alumina-N SepPak Light cartridges were obtained from Waters Corporation (Waltham, Mass.). A Mini-scan radio-TLC scanner from Bioscan, Inc was used to monitor the radiochemical purity. Anion chromatography HPLC (Dionex IC-2100, AS19 analytical column 4.7×150 mm, eluent 35 mM KOH, sample volume 25 uL, flow rate 1 mL/min) was calibrated to measure .sup.18F-TFB and .sup.18F-TFB concentrations with conductivity and radioactivity detectors in series. The method was validated by separation of a series of anions (F.sup.−, Cl.sup.−, Br.sup.−, I.sup.−, NO.sub.3.sup.−, CO.sub.3.sup.2−, and BF.sub.4.sup.−) and OH.sup.− was negated by the system, Residual organic solvents were analyzed by GC (helium carrier gas flow at 10 cc/min through a MXTWAX column (Restek, Bellefonte, Pa., 0.53 mm ID, 30 m length)). The temperature program was 4 min at 35° C., followed by a temperature ramp of 4° C. per min to a maximum of 150° C.

Preparation of BF.SUB.3..THF Complex Solution

[0052] A solution of BF.sub.3.THF complex in petroleum ether was prepared freshly within 30 min of the radiosynthesis of .sup.18F-TFB (FIG. 1A). The luer opening of a 20 mL polypropylene syringe was melted closed. A silicone stopper was placed in the opposite opening. A 20 mL sterile vial with PEEK tubing was connected to the 20 mL syringe as shown in FIG. 1. The syringe body was completely filled with petroleum ether and about half of the sterile vial was also filled with petroleum ether (PE). BF.sub.3 gas (˜5 mL) was flowed into the syringe from a BF.sub.3 cylinder through a PEEK tube, thereby displacing the corresponding petroleum ether to the sterile vial. After removal of the BF.sub.3 addition tube, 0.5 mL THF was injected through the silicone stopper. The BF.sub.3 gas was dissolved in the added THF quickly, and petroleum ether was sucked back into the syringe from the auxiliary vial without entry of atmospheric air. The tube was removed and the mixture became a homogenous solution with gentle shaking. The concentration of the BF.sub.3 in the solution was ˜1.8 μmol/mL. (FIG. 1A) FIG. 1B shows an alternative method using a simple manifold/syringe system. As shown in FIG. 1B, Step 1 you fill the syringe A with 5 ml BF.sub.3 and Syringe B with PE/THF mixture; step 2 you switch the valve to the right and step 3 you push PE/THF mixture from Syringe B to the syringe A. Preparation of in-house-made Lewatit MP-64 cartridge

[0053] A 1 mL syringe body was filled with 300 mg Lewatit® MP-64 (carbonate form) and stoppered with some degreasing cotton at both sides. The syringe was cut off and jointed with another 1 mL syringe body using a sheath of silicone tubing (FIG. 2).

[.SUP.18.F]TFB Synthesis Method

[0054] An automated synthesis of .sup.18F-TFB was developed for the preparation of .sup.18F-TFB (FIG. 3). .sup.18F-fluoride (37.6-40.5 GBq) was made by irradiation of 2.5 mL [.sup.18O]water with 65 uA for 15 min in GE PETtrace cyclotron, and then delivered to the hot cell and trapped on a QMA (46 mg, carbonate form) cartridge. .sup.18O-enriched water was collected using valve V13. The QMA cartridge was rinsed with 10 mL anhydrous acetone, and flushed with nitrogen for 100 seconds. The freshly prepared BF.sub.4.THF complex solution (5 mL) was filtered by an in-house-made Lewatit® MP-64 cartridge (200400 mg), and then passed through the QMA cartridge within 10 s to react with the trapped .sup.18F-fluoride to form .sup.18F-TFB. The QMA cartridge was rinsed with a solution of 10 mL THF, flushed for 100 s with nitrogen, and rinsed with 13 mL water to further remove impurities. The QMA was then treated with 5 mL sterile 0.9% NaCl, USP solution (saline) to elute into a product vial pre-loaded with an additional 5 mL saline.

[0055] The crude .sup.18F-TFB product solution was further purified from unreacted .sup.18F-fluoride by passing three alumina-N SepPak Light cartridges before passage through a 0.2 μM sterilizing filter with final collection of the .sup.18F-TFB in a product vial. (FIG. 3)

Quality Control

[0056] The product .sup.18F-TFB was analyzed for radiochemical purity by both radio-TLC (MeOH, Rf=0.8-0.85) and anion chromatography HPLC with radioactivity detector (Dionex IC-2100, AS19 analytical column: 4.7×150 mm; eluent: 35 mM KOH; sample volume: 25.L; flow rate: 1 mL/min; retention times: 7.6 min for .sup.18F-TFB, 7.8 min for .sup.18F-TFB). Chemical purity and specific activity were analyzed by anion chromatography HPLC (retention times: 3.5 min for fluoride, 4.3 min for chloride, and 7.6 min for BF.sub.4—). Residual organic solvents were analyzed by GC (helium carrier gas flow at 10 cc/min through a MXTWAX column (Restek, Bellefonte, Pa., 0.53 mm ID, 30 m length)).

In Vivo Imaging

[0057] Studies with mice were performed under approval of the Mayo Clinic Institutional Animal Care and Use Committee. Dynamic PET imaging was performed in hNIS-expressing C6 glioma xenografted athymic mice following retro-orbital injection ˜1.1 MBq Na .sup.18F-TFB at different specific activities (10-0.001 mg TFB/Kg mouse) to assess hNIS activity with .sup.18F-TFB. In this xenograft model, one flank has hNIS-negative C6 glioma tumor xenograft and the other flank had hNIS-expressing C6 glioma xenograft.

[0058] PET scans were acquired for 60 min followed by an X-ray scan using the GENISYS4 PET imaging system (Sofie Biosciences, CA). The images from 40 hNIS-expressing C6 glioma xenografted mice were analyzed for Standardized Uptake Value (SUV) in tumor, stomach, and thyroid using AMIDE image processing software (20). The SUV in tumor was normalized with SUV in stomach to account for difference in .sup.18F-TFB bioavailability in different animals due to competing uptake in normal organs like thyroid, salivary glands and stomach.

Immunohistochemistry

[0059] Tumors from 5 age-matched hNIS-expressing C6 glioma xenografted mice were harvested and formalin-fixed. The tumors were then equilibrated in 15% and 30% sucrose with phosphate buffer for 4 days, and frozen for cryo-sectioning. A series of adjacent sections were cut on a cryostat. Each section was 10 μm thick, and mounted onto charged slides (Superfrost Plus slides, Fisherbrand). After drying, the sections were blocked with 10% goat serum for 4 h at room temperature, followed by overnight incubation with 1:4000 dilution of rabbit Anti-human NIS antibody SJ1 (Imanis Life Sciences, Rochester, Minn.) in PBS with 10% goat serum at 4° C. The non-specific anti-human NIS antibody SJ1 in sections was 3× washed in PBS-Tween 20 (0.05%) for 15 min each at room temperature. The sections were incubated with secondary antibody, Alexa Fluor 488 goat anti-rabbit IgG (H+L) antibody (Life Technologies, CA) at a dilution of 1:4000 in PBS for 45 min at room temperature. The non-specific secondary antibody was thrice washed in PBS-Tween 20 (0.05%) for 15 min each at room temperature. Following washing, the sections were counter-stained with nuclear DAPI stain. The sections were then cover-slipped with mounting medium and imaged using a Nikon Eclipse Ti inverted microscope at 10× magnification.

Data Analysis and Statistics

[0060] Data is expressed as mean±SD. MicroSoft Excel Solver was used to regress the tumor/stomach ratios of .sup.18F-TFB uptake using a nonlinear least-squares regression algorithm.

Results

Radiosynthesis and Quality Control of .SUP.18.F-TFB

[0061] After irradiation, .sup.18F-fluoride in .sup.18O-enriched water was delivered to the hot cell and quantitatively trapped on the QMA cartridge. The QMA cartridge was rinsed with acetone (10 mL) and flushed with nitrogen for 100 s. The freshly prepared BF.sub.3.THF complex solution (5 mL) was passed through an inhouse-made Lewatit® MP-64 cartridge and the QMA cartridge as a single bulk passage of solvent lasting ˜10 s. .sup.18F-TFB largely remained on the cartridge while 20-40% of the .sup.18F-fluoride was released from the QMA cartridge, possibly by formation of .sup.18F-HF under the acidic conditions caused by BF.sub.3. The QMA cartridge was rinsed with a solution of 10 mL THE and 13 mL water to remove the impurities from the QMA cartridge. To decrease the residual acetone and THF in the final product, 100 s of nitrogen flush was applied after THF rinsing. .sup.18F-TFB was eluted from the QMA cartridge with 5 mL sterile saline to the product vial, in which 5 mL sterile saline was added in advance for further dilution of the product. The crude product solution was purified by trapping the unreacted .sup.18F-fluoride on three alumina-N SepPak Light cartridges. Using two alumina-N SepPak Light cartridges, the radiochemical purities were 93-96%. Radiochemical purity was increased to >98% by use of an additional alumina-N SepPak Light cartridge. The amount of starting BF.sub.3 for the reaction was found to be critical to determine the radiochemical yields and specific activities. Firstly, 5 mL BF.sub.3.THF/PE solution (˜45 μmol) was used in the reaction and 8.33-0.65 μmol unlabeled TFB with 35.0±3.6% yields were obtained. To decrease the amount of BF.sub.3 for the reaction, the BF.sub.3.THF/PE solution was passed through Lewatit® MP-64 resin immediately before passage through the QMA cartridge. Lewatit® MP-64 is an anion exchange resin, which contains crosslinked polystyrene matrix with tertiary amine and quaternary ammonium functional groups. Separate analysis of the post-Lewatit® MP-64 filtrate showed that 70%, 80% and 90% of the BF.sub.3 in the original 5 mL BF.sub.3.THF/PE solution was retained on 200, 300 and 400 mg Lewatit® MP-64 resin, respectively. Thus, the influence of the Lewatit® MP-64 was not only to retain unlabeled TFB, but also to reduce the amount of BF.sub.3 reactant. Evidently, the BF.sub.3 tertiary amine complex formed on the Lewatit® MP-64 was stronger than the BF.sub.3.THF complex in the solution, which result in retention of BF on the resin.

[0062] Investigations with 200 to 400 mg Lewatit® MP-64 resin (Table 1) resulted in the production of unlabeled TFB and product .sup.18F-TFB in proportional amounts (FIG. 4). More Lewatit® MP-64 resin gave less BF.sub.3 in the reaction, resulting in lower radiochemical yield with proportionately less unlabeled TFB (Table 1). Thus, the specific activity of the .sup.18F-TFB product improved as the amount of Lewatit® MP-64 resin is increased, however, at the cost of decreased radiochemical yield.

TABLE-US-00001 TABLE 1 Dependence of overall radiochemical yield and specific activity (N = 3) of .sup.18F-TFB product on the amount of Lewatit ™ MP-64 resin. Reactions were performed with starting .sup.18F-fluoride radioactivities of 15-37 MBq. Lewatit ™ MP-64 Unlabeled Uncorrected radiochemical resin (mg) BF.sub.4.sub.− (μmol) yield (%) 0 8.33 ± 0.65 35.0 ± 3.6 200 2.43 ± 0.12 30.7 ± 2.1 250 1.97 ± 0.15 27.3 ± 1.2 300 1.13 ± 0.15 22.3 ± 2.1 350 0.55 ± 0.05 16.0 ± 1.7 400 0.23 ± 0.06 11.7 ± 1.5

[0063] A 300 mg Lewatit® MP-64 resin was used for a high radioactivity level synthesis (40-44 GBq) as a compromise between radiochemical yield and specific activity. The radiochemical yield of .sup.18F-TFB was 20.0±0.7% (n=3) uncorrected in a synthesis time of 10 min. Radiochemical purity was >98% as shown on silica gel TLC (FIG. 5) and anion chromatography HPLC (FIG. 6). Specific activities of 8.84±0.56 GBq/μmol (n=3) were achieved from starting .sup.18F-fluoride activities of 40-44 GBq. In the HPLC analysis of the final product, a carbonate peak at 3.6 min and an unknown impurity peak at 3.8 min were initially observed. Investigation revealed these to be contaminants present on the stock QMA and alumina cartridges. By pretreating the cartridges with 20 mL 0.9% saline and 20 mL water, the peaks were reduced to a trace amount.

[0064] Residual acetone and THF were obtained in concentrations of 63-135 ppm and 24-27 ppm, respectively, which were well under the allowed solvent concentration limits (acetone 5000 ppm, THF 720 ppm) set by the International Conference on Harmonization (ICH) for technical requirements for registration of pharmaceuticals for human use (FIG. 7).

Stability of .SUP.18.F-TFB

[0065] After the synthesis, a sample was diluted with water for the analysis. With the eluent of methanol on silica gel plate, purities of >98% were obtained on the radio-TLC scanner. After 20 h, radio-TLC gave a >96% radiochemical purity and HPLC analysis of the product sample showed the .sup.18F-TFB peak was chemically stable. A slow hydration of .sup.18F-TFB in water may resulted in the slow decrement of the radiochemical purity. HPLC analysis of a NaBF.sub.4 stock solution (stored for 7 month at room temperature) showed 50% of TFB was decayed and gave a peak of fluoride at 3.4 min.

In Vivo Imaging Studies

[0066] Robust uptake of .sup.18F-TFB was observed in thyroid, stomach, bladder and hNIS-expressing tumors of the C6-glioma xenograft mouse model (FIGS. 9 and 10), No uptake of .sup.18F-TFB was observed in hNIS-negative tumors, confirming specificity of uptake of .sup.18F-TFB to hNIS-expressing tumors. .sup.18F-TFB uptake in thyroid and hNIS-expressing tumor showed a bi-phasic kinetic: rapid uptake over the first 10 min was followed by slower uptake until 30 min with little subsequent change. The stomach showed linear increase in .sup.18F-TFB uptake over 60 min. Stomach uptake was independent of specific activity of .sup.18F-TFB while uptake in hNIS-expressing tumor and thyroid was dependent on specific activity of .sup.18F-TFB. The uptake of .sup.18F-TFB by hNIS-expressing tumor was higher at high specific activity (>13 MBq/μmol) as compared to lower specific activity (3 MBq/μmol). This trend was also seen for thyroid.

[0067] For a more detailed analysis of the effect of specific activity of .sup.18F-TFB on uptake in hNIS-expressing tumors, a 60 min time-point was chosen and a range of specific activities (10-0.001 mg TFB injected/kg mouse weight) was tested. The uptake in tumor was normalized to stomach uptake to account for differences in bioavailability of .sup.18F-TFB across animals. The uptake of .sup.18F-TFB in hNIS-expressing C6 tumor showed dependence on specific activity at 10-0.5 mg TFB/Kg mouse weight or 0-10 MBq/μmol considering ˜1.1 MBq radioactivity injected in a ˜25 g mice. But this trend was not observed for higher specific activities (>10 MB/μmol TFB or <0.5 mg TFB/Kg mouse weight) (FIG. 11). At these higher specific activities the uptake of .sup.18F-TFB was no longer dependent on specific activity but exhibited high variability. Immunohistochemistry analysis for hNIS in tumor sections from 5 mice showed significant intra-tumoral and inter-tumoral variability of expression of hNIS (FIG. 12) that may play a role in the variability of .sup.18F-TFB uptake observed in tumors.

Discussion

[0068] BF.sub.3 is a versatile Lewis acid and widely used in the chemistry. It is known that BF.sub.3 will form TFB in the presence of water via a fluoride exchange reaction, which was well documented [17, 18]. Therefore, the present disclosure aimed to synthesize high specific activity .sup.18F-TFB with the reaction of BF.sub.3 and .sup.18F-fluoride. The .sup.18F-fluoride was conveniently trapped on a QMA cartridge and the reaction was found to proceed by addition of a BF.sub.3 complex in solution. A variety of BF.sub.3 complexes (e.g. BF.sub.3-pyridine, BF.sub.3-Et.sub.3N, BF.sub.3-MeOH, BF.sub.3-EtOH, BF.sub.3.Et.sub.2O and BF.sub.3.THF) were tested in the reaction. With respect to yield and specific activity, BF.sub.3.THF complex gave the best results. Therefore, BF.sub.3.THF complex was used for the further optimization. In initial exploration, only 5-10% radiochemical yields of .sup.18F-TFB were obtained with commercially available BF.sub.3.THF solutions. To improve radiochemical yields of .sup.18F-TFB, a BF.sub.3.THF/PE solution was freshly prepared with BF.sub.3 gas in a simple apparatus described above (FIG. 1A or 1B). To improve specific activity, the freshly prepared BF.sub.3.THF/PE solution was passed through Lewatit® MP-64 resin immediately before passage through the QMA cartridge. As shown in Table 1, depending on the amount of Lewatit® MP-64 resin used in the process, a trade-off was found to exist between radiochemical yield and specific activity of the .sup.18F-TFB product.

[0069] Using 300 mg Lewatit® MP-64 resin was selected for a high radioactivity level synthesis (40-44 GBq) as a compromise between radiochemical yield and specific activity. Three runs in this condition achieved specific activities of 8.84±0.56 GBq/.mol and uncorrected radiochemical yields of 20.0±0.7%. In some embodiments, to optimize specific activity at the sacrifice of radiochemical yield, the use of 400 mg Lewatit® MP-64 resin and 80 GBq starting activity would result in .sup.18F-TFB specific activity of approximately 30 GBq/μmol with an overall uncorrected radiochemical yield near about 12%. The high specific activities obtained by our method are unlikely to be obtained with the previously reported isotope exchange method [14].

[0070] The methods provided improve upon the isotope exchange method by providing significantly enhanced radiochemical yields (˜31% with use of 200 mg Lewatit® MP-64 resin versus ˜10% for isotopic exchange [14]) at moderate specific activity (˜5 GBq/μmol (estimated) versus ˜1 GBq/μmol [14]). A putative chemical reaction mechanism for synthesis of .sup.18F-TFB via BF.sub.3 is shown in scheme 1. BF.sub.3 hydrates with water quickly to form HBF.sub.3OH [17]. Although the BF.sub.3.THF complex solution is prepared in near anhydrous conditions, the QMA cartridge is likely containing trace amounts of water after trapping of the .sup.18F-fluoride and treatment with acetone and nitrogen. Indeed, the .sup.18F-fluoride itself may be in a hydrated form [19] on the QMA cartridge. Although it is possible that BF.sub.3 reacts directly with .sup.18F-fluoride ion, not to be bound by any theory, it is believed that HBF.sub.3OH is the more likely intermediate to react with .sup.18F-fluoride to make .sup.18F-TFB. In the presence of water, HBF.sub.3OH may react further to form a series of intermediates, which ends with the release of boric acid and HF [17]. The release of .sup.19-fluoride from BF.sub.3 may represent a source of unlabeled fluoride that can decrease the specific activity of the product. (Scheme 1)

[0071] Jauregui-Osoro et al. (14) estimated that the administration of ˜400 MBq .sup.18F-TFB synthesized by the conventional method to a human subject would result in a plasma concentration of ˜0.1 μM TFB. Considering the IC.sub.50 of TFB to be 0.1-1 μM for inhibition of iodine uptake by NIS in thyroid (21), it is desirable to increase .sup.18F-TFB specific activity above ˜5 GBq/μmol to avoid a pharmacological effect (14). The presently reported synthesis method for .sup.18F-TFB achieves this goal. At a specific activity of 8 GBq/μmol, a ˜400 MBq administered dose of .sup.18F-TFB would give an estimated in vivo concentration of ˜0.02 μM TFB which should not exhibit a pharmacologic effect.

[0072] To evaluate the influence of .sup.18F-TFB specific activity on in vivo uptake by NIS-expressing tissues, we employed a hNIS-expressing C6 tumor xenograft mouse model. As expected, .sup.18F-TFB was taken up by selected organs expressing NIS in the xenograft mouse model. Among the select organs, thyroid and hNIS-expressing tumor were sensitive to specific activity of .sup.18F-TFB as .sup.18F-TFB was being transported using NIS in these organs. On the other hand, in stomach, which also possesses NIS (22-24), the uptake of .sup.18F-TFB was found to be independent of its specific activity. The insensitivity of .sup.18F-TFB uptake to specific activity in stomach was not clarified, but may point to different kinetic properties of the NIS protein in gastric mucosal cells as compared to thyroid and hNIS-expressing tumor (23,24). Another possible explanation is that .sup.18F-TFB entering the gastric epithelial cells is immediately effluxed into the stomach lumen such that the intracellular concentration (e.g. in gastric parietal cells) is never in equilibrium with the interstitial fluid so unidirectional transport continues unabated. A biphasic response was observed in hNIS-expressing tumor uptake of .sup.18F-TFB versus administered dose of unlabeled TFB. The .sup.18F-TFB uptake in tumor decreased with increasing amount of administered TFB over the range of 0.5-10 mg TFB/kg mouse weight, but this trend was not observed for higher specific activities (<0.5 mg TFB/kg mouse weight). Rather, the tumor uptake was constant but highly variable for administered TFB doses <0.5 mg/kg. The reason for this trend is not clear but it is possible that at high specific activity, factors other than specific activity contribute to the variability, such as variability in the inter- and intra-tumoral expression and/or activity of hNIS, number of tumor cells expressing hNIS, heterogeneity of tumor perfusion and/or oxygenation, variability of tumor size or the indirect influence of differences in the physiological distribution of radiotracer to other areas of the body. The large variation seen in hNIS expression levels in the C6 glioma xenografts may reflect the fact that the C6-hNIS transduced cell line was not a clonal population but included high, low and negative expressing cells. The ability of the .sup.18F-TFB-PET method to reliably report on viral infection depends on hNIS expression within infected cells and possibly post-translational events that influence hNIS transporter activity (25). These considerations must also be kept in mind for future studies in monitoring hNIS transduction in human studies that may also entail significant heterogeneity of hNIS expression following viral therapies. Nonetheless, it was encouraging to observe a broad range of specific activities of .sup.18F-TFB over which tumor uptake was robust.

Conclusion

[0073] A solid-phase supported synthesis of .sup.18F-TFB was developed via radiofluorination of BF.sub.3. With the optimized condition, the radiochemical yield of .sup.18F-TFB was 20.0±0.7% (n=3) uncorrected in a synthesis time of 10 min. Specific activities of 8.84±0.56 GBq/μmol (n=3) were achieved with starting .sup.18F-fluoride radioativities of 40-44 GBq. This method offers a convenient synthesis of high specific activity .sup.18F-TFB. A positive correlation was observed between specific activity of .sup.18F-TFB and hNIS-expressing C6 glioma xenografts for lower specific activities resulting in administration of TFB exceeding 0.5 mg/kg in mice. The increased specific activity of .sup.18F-TFB may allow for enhanced PET imaging of hNIS reporter in future human studies.

REFERENCES FOR EXAMPLE 1

[0074] [1] Chung J K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002; 43:1188-200. [0075] [2] Penheiter A R, Russell S J, and Carlson S K. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther 2012; 12:33-47. [0076] [3] Ahn B-C. Sodium Iodide Symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics 2012; 2:392-402. [0077] [4] Daniels G H and Haber D A. Will radioiodine be useful in treatment of breast cancer? Nat Med 2000; 6:859-60. [0078] [5] Dai G, Levy O, and Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379:458-60. [0079] [6] Eskandari S, Loo D D F, Dai G, Levy O, Wright E M, and Carrasco N. Thyroid Na+/I. Symporter: mechanism, stoichiometry, and specificity. J. Biol. Chem 1997; 272:27230-8. [0080] [7] Sparagana M, Little A, and Kaplan E. Rapid evaluation of thyroid nodules using 99mTc-Pertechnetate scanning. J Nucl Med 1970; 11:224-5. [0081] [8] Ryo U Y, Vaidya P V, Schneider A B, Bekerman C, and Pinsky S M. Thyroid imaging agents: a comparison of I-123 and Tc-99m pertechnetate. Radiology 1983; 148:819-22. [0082] [9] Groot-Wassink T, Aboagye E O, Wang Y, Lemoine N R, Reader A J, and Vassaux G. Quantitative imaging of Na/I Symporter transgene expression using positron emission tomography in the living animal. Mol Ther 2004; 9:436-42. [0083] [10] Schmitz J. The production of [124I]iodine and [86Y]yttrium. Eur. J. Nucl. Med. Mol. Imag 2011; 38:4-9. [0084] [11] Anbar M, Guttmann S, and Lewitus Z. The Accumulation of Fluoroborate Ions in Thyroid Glands of RatS1. Endocrinology 1960; 66:888-90. [0085] [12] Anbar M, Guttmann S, and Lewitus Z. Effect of Monofluorosulphonate, Difluorophosphate and Fluoroborate Ions on the Iodine Uptake of the Thyroid Gland. Nature 1959; 183:1517-8. [0086] [13] Anbar M and Guttmann S. The Isotopic Exchange of Fluoroboric Acid with Hydrofluoride Acid. J. Phys. Chem 1960; 64:1896-9. [0087] [14] Jauregui-Osoro M, Sunassee K, Weeks A J, Berry D J, Paul R L, Cleij M, et al. Synthesis and biological evaluation of F-18 tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur. J. Nucl. Med. Mol. Imag 2010; 37:2108-16. [0088] [15] Weeks A J, Jauregui-Osoro M, Cleij M, Blower J E, Ballinger J R, and Blower P J. Evaluation of [.sup.18F tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS. Nuclear Medicine Communications 2011; 32:98-105. [0089] [16] Youn H, Jeong J M, and Chung J-K. A new PET probe, F-18-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine. Eur. J. Nucl. Med. Mol. Imag. 2010; 37:2105-7. [0090] [17] Wamser C A. Equilibria in the System Boron Trifluoride-Water at 25<C. J. Am. Chem. Soc 1951; 73:409-16. [0091] [18] Wamser C A. Hydrolysis of Fluoboric Acid in Aqueous Solution. J. Am. Chem. Soc 1948; 70:1209-15. [0092] [19] Cai L, Lu S, and Pike V W. Chemistry with F-18 fluoride ion. Eur. J. Org. Chem 2008:2853 73. [0093] [20]. Loening A M, Gambhir S S. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003; 2:131-137. [0094] [21]. Lecat-Guillet N, Ambroise Y. Discovery of aryltrifluoroborates as potent sodium/iodide symporter (NIS) inhibitors. Chem Med Chem. 2008; 3:1207-1209. [0095] [22]. Portulano C, Paroder-Belenitsky M, Carrasco N. The Na+/I− symporter (NIS): mechanism and medical impact. Endocr Rev. 2014; 35:106-149. [0096] [23]. Wolosin J M. Ion transport studies with H+-K+-ATPase-rich vesicles: implications for HCl secretion and parietal cell physiology. Am J Physiol. 1985; 248:G595-607. [0097] [24]. R. McG. Harden, W. D. Alexander, J. Shimmins, D. Chisholm. A comparison between the gastric and salivary concentration of iodide, pertechnetate, and bromide in man. Gut. 1969; 10:928-930. [0098] [25]. Kogai T I, Brent G A. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012; 135:35
The citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.

Example 2: Biodistribution and Radiation Dosimetry of .SUP.18.F-Tetrafluoroborate (.SUP.18.F-TFB) in Healthy Human Subjects

[0099] .sup.18F-tetrafluoroborate (.sup.18F-TFB) has been identified as a promising iodide analog for imaging of thyroid cancer and monitoring of NIS expression as a reporter probe in viral therapy applications. This Example demonstrates the pharmacokinetics, biodistribution and radiation dosimetry of high-specific activity .sup.18F-TFB in healthy human subjects. Methods: .sup.18F-TFB was synthesized via .sup.18F-fluorination of BF.sub.3 with specific activity of 2.2±0.9 GBq/μmol. Dynamic PET/CT imaging over 4 h was performed after intravenous administration of .sup.18F-TFB (333-407 MBq) in 4 female and 4 male healthy volunteers (35±10 year old). Initial scanning over the heart allowed definition of the blood pharmacokinetics, while whole body scans at 2 and 3.5 h provided data for biodistribution and radiation dosimetry. Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to determine the safety of .sup.18F-TFB administration. Results: .sup.18F-TFB administration was well tolerated with no significant findings on vital signs or clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of radioactivity with the two rapid clearance phases over the first 30-45 min, followed by a slower clearance phase. HPLC analysis showed insignificant .sup.18F-labeled metabolites in the blood and urine over the length of the study (4 h). At 2 h p.i., high uptakes were seen in thyroid, stomach, salivary glands, and kidney. Urinary clearance of .sup.18F-TFB was prominent. Minor changes were seen in .sup.18F-TFB biodistribution from 2-4 h p.i. A low level of metabolic defluorination was evidenced by low accumulation of .sup.18F-radioactivity in bone (SUV=1.4±0.5 in males, SUV=1.3±0.9 in females at 3.5 h). Conclusion: This initial study in healthy human subjects showed .sup.18F-TFB to be safe, metabolically stable, and distribute in the human body similar to other iodide analogs with prominent physiologic distribution to thyroid, stomach, salivary glands and bladder, with thyroid as the dose-critical organ. .sup.18F-TFB can be used as a hNIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.

[0100] Example 1 demonstrates high specific radioactivity syntheses of .sup.18F-TFB via the reaction of boron trifluoride (BF.sub.3) and .sup.18F-fluoride. We demonstrated the relationship of .sup.18F-TFB specific radioactivity and PET-delineated radiotracer uptake in NIS-transfected C6-glioma xenograft bearing mice, confirming the desirability of high specific radioactivity to avoid saturation effects at the NIS transporter. In this study, we report PET/CT imaging data with .sup.18F-TFB in healthy male and female participants to describe physiologic distribution of the radiotracer and allow calculation of radiation dosimetry estimates.

Materials and Methods

[0101] Radiotracer Synthesis

[0102] .sup.18F-TFB was prepared and formulated in sterile 0.9% NaCl under cGMP conditions as previously described (12). Decay-corrected radiochemical yields of 32±2% and radiochemical purities (RCPs) >98% were obtained. Specific radioactivity of 2.2±0.9 GBq/μmol was achieved from starting .sup.18F-fluoride radioactivity of 20-31 GBq. In vitro RCP remained >96% up to 8 h at room temperature.

[0103] Human Participants

[0104] Approval of the study was obtained from the Mayo Clinic Institutional Review Board and all participants provided informed consent. Four male (36±14 y) and four female (35±8 y) healthy volunteers were enrolled in the study. Participants were excluded that had previous diagnosis of cancer or clinically significant cardiovascular, renal, pulmonary, metabolic, and endocrine (thyroid) diseases. Participants were not required to fast prior to the imaging study but instructed to remain well-hydrated.

[0105] PET/CT Imaging Protocol

[0106] The imaging protocol is illustrated in FIG. 13. After voiding of the bladder, participants were positioned in a GE 690XT PET/CT scanner (GE HealthCare, Waukesha, Wis.) in a supine position with the heart in the center of the axial field of view. Intravenous catheters were placed in both arms for radiotracer injection and blood sampling. Computed tomography scans of the thorax were initially acquired in the preparation for a dynamic PET data acquisition over the heart for the first 45 min following commencement of radiotracer administration. .sup.18F-TFB (333-407 MBq) was administered over 1 minute into one of the catheters. The frame sequence for initial dynamic PET acquisition was 15×4, 8×15, 4×30, and 8×300 seconds. Following the dynamic heart scan, the participants were allowed a break from the scanner, during which time voided their bladders. Two additional PET/CT scans, from the vertex of the skull to mid-thigh, were performed at 2 hours and 3.5 hours respectively. The last PET/CT scan was completed ˜4 h post-injection.

[0107] Measurements in Venous Blood and Urine Samples

[0108] Urine was collected after each PET/CT scan (approximately 55, 160, 250 min), and venous blood samples were collected at 40, 145 and 235 min, post-injection, as shown in FIG. 13. Blood samples (3-4 mL) were collected in heparinized tubes and placed on ice. The blood samples were centrifuged at 3000 g for 5 min to obtain plasma. Urine was measured for urine volume and radioactivity concentration as measured in a calibrated gamma counter. Analysis for metabolites in plasma and urine was performed by ion-chromatography HPLC, allowing estimation of the fraction of radioactivity as nonmetabolized .sup.18F-TFB.

[0109] Safety Measurements for .sup.18F-TFB Administration

[0110] Vital signs (heart rate, systolic and diastolic blood pressures, respiratory rate, and temperature) were measured prior to .sup.18F-TFB administration and at 45 and 240 min post-injection. Venous blood samples were taken prior to .sup.18F-TFB administration and at ˜240 min post-injection for a panel of clinical laboratory tests to evaluate the safety of the radiotracer administration.

[0111] PET/CT Image Analysis

[0112] All PET scans images were reconstructed using 3D OSEM and time-of-flight reconstruction. Volumes of interest (VOI's) of organs were drawn using PMOD software (Ver. 3.5). Standardized Uptake Values (SUVs) normalized to body weight were then calculated for each VOI. Time-activity curves (TACs) were evaluated from the initial dynamic scan over the heart for left-ventricular blood pool, lung and liver regions.

[0113] Radiation Dosimetry Estimation

[0114] Radiation dosimetry estimates were calculated from organ residence times using OLINDA software (Ver. 1.1), assuming a bladder voiding interval of 3.5 h. Gender-specific organ masses for the conversion of SUV to disintegrations per organ per unit radioactivity administered (Bq-hr/Bq) were taken from Schlein et al. (15).

[0115] Statistics

[0116] Data are expressed as mean SD. Statistical significance of differences in SUV values between PET/CT scans were determined by ANOVA.

Results

[0117] Pharmacokinetics of .sup.18F-TFB

[0118] The initial 45-min dynamic PET/CT scan over the heart allowed evaluation of the early kinetics of .sup.18F-TFB in the left-ventricular blood pool (LVBP) as in indication of the pharmacokinetics of this radiotracer. FIG. 14 shows the time-activity curves in LVBP, lung, and liver in a representative participant. Peak values of radioactivity concentration were seen at ˜1 min for LVBP and lung regions, whereas the peak in liver was at ˜2 min post-administration of .sup.18F-TFB. Blood clearance was multiphasic, with clearance proceeding to the end of the 4-h measurement period. Continued radiotracer washout was also seen in lung and liver.

[0119] Metabolite Analysis

[0120] HPLC metabolite analysis of plasma samples at 40 min p.i. showed >97% of radioactivity to be in the form of metabolically intact .sup.18F-TFB (Table 2). Similarly, all urine samples taken from urine collections at approximately 50, 160, 250 min showed >97% of radioactivity in the form of .sup.18F-TFB. The accumulated percentage of administered .sup.18F-TFB in the urine at the end of study (˜250 min) was 40±4% for males and 47±7% for females. Thus, renal clearance of nonmetabolized .sup.18F-TFB is a major excretion pathway for .sup.18F-TFB.

TABLE-US-00002 TABLE 2 Metabolite analysis of .sup.18F-TFB in plasma and urine of healthy participants 40 min.sup.a 145 min.sup.a 235 min.sup.a Accumulative Males Females Males Females Males Females Males Females Whole blood (SUV) 3.0 ± 0.2 3.1 ± 0.9 2.1 ± 0.2 1.7 ± 0.4 1.7 ± 0.2 1.4 ± 0.4 — — Plasma (SUV) 3.8 ± 0.2 3.8 ± 1.0 2.8 ± 0.3 2.1 ± 0.5 2.0 ± 0.1 1.7 ± 0.5 — — Urine (% Dose) 15 ± 2.sup.b  16 ± 3  13 ± 3  1.8 ± 3.sup.  10 ± 2.sup.b  12 ± 2  40 ± 4.sup.b 47 ± % Intact Plasma 97 ± 2  97 ± 3.sup.c  —.sup.d —.sup.d —.sup.d —.sup.d — — .sup.18F-TFB Urine 96 ± 2  98 ± 1  97 ± 2  98 ± 1  98 ± 1  97 ± 2  — — Values are mean ± SEM (n = 4) .sup.aTime-points are shown for blood samples; urine samples were collected ~10 min later. .sup.bNo urine in third collection in one of the male subjects. .sup.cOne plasma sample was not used because precipitate was observed in the HPLC analysis. .sup.dMetabolite data were not obtained in second and third plasma samples analysis because the low radioactivity levels were below detection limit. Biodistribution of .sup.18F-TFB Representative images from the whole-body PET/CT scan at 2 h post-injection are shown in FIG. 15 and the biodistribution data are summarized in Table 3. Robust uptake of .sup.18F-TFB was observed in thyroid, stomach, salivary glands, and kidney. Prominent clearance of tracer through kidney to bladder was also observed. Minor differences were observed in the SUV values between the first (2 h) and second (3.5 h) whole body PET/CT scans, showing the tracer distribution to be stable at least after 2 h. Bone uptake was moderately increased from 2 to 3.5 h in males, indicating a low level of defluorination of .sup.18F-TFB, but the increase was not statistically significant in females. indicates data missing or illegible when filed

[0121] Biodistribution of .sup.18F-TFB

[0122] Representative images from the whole-body PET/CT scan at 2 h post-injection are shown in FIG. 15 and the biodistribution data are summarized in Table 3. Robust uptake of .sup.18F-TFB was observed in thyroid, stomach, salivary glands, and kidney. Prominent clearance of tracer through kidney to bladder was also observed. Minor differences were observed in the SUV values between the first (2 h) and second (3.5 h) whole body PET/CT scans, showing the tracer distribution to be stable at least after 2 h. Bone uptake was moderately increased from 2 to 3.5 h in males, indicating a low level of defluorination of .sup.18F-TFB, but the increase was not statistically significant in females.

TABLE-US-00003 TABLE 3 PET/CT-derived distribution of .sup.18F-TFB in healthy participants 2 h post-injection (SUV) 3.5 h post-injection (SUV) Organ Males Females Males Females Bone 0.80 ± 0.33 0.74 ± 0.20  1.4 ± 0.5* 1.3 ± 0.9 Brain 0.39 ± 0.14 0.42 ± 0.15 0.74 ± 0.26 0.61 ± 0.34 Breast — 2.8 ± 0.4 — 3.9 ± 1.4 Gallbladder 2.7 ± 1.5 3.7 ± 1.0 4.2 ± 1.7 5.0 ± 1.6 Intestines 2.9 ± 1.0 5.0 ± 2.7 4.4 ± 1.0 6.0 ± 3.1 Kidney 7.0 ± 2.5 5.6 ± 0.7 11 ± 3  6.3 ± 2.4 Liver 2.3 ± 1.0 2.7 ± 0.5 3.6 ± 1.2 3.5 ± 1.6 Lung 1.0 ± 0.4 1.2 ± 0.4 1.7 ± 0.6 1.5 ± 0.8 Muscle 0.71 ± 0.31 0.65 ± 0.35 0.96 ± 0.31 0.78 ± 0.54 Myocardium 3.2 ± 0.9 2.8 ± 0.5 5.0 ± 0.9 3.8 ± 1.8 Pancreas 3.4 ± 0.7 3.1 ± 1.7 6.2 ± 2.1 3.0 ± 1.2 Parotid 11 ± 9  20 ± 11 16 ± 13 25 ± 15 Spleen 4.1 ± 1.2 4.3 ± 1.0 6.3 ± 1.1 5.5 ± 2.8 Stomach 33 ± 15 72 ± 10 70 ± 32 51 ± 18 Thyroid 55 ± 31 50 ± 11  82 ± 42* 58 ± 12 Values are mean ± SEM (n = 4) *p < 0.05 versus 2 h

[0123] Radiation Dosimetry Estimates

[0124] Table 4 shows organ residence times derived from the biodistribution data. Bladder residence time was estimated by the bladder emptying model within the OLINDA software, assuming a 3.5 h bladder voiding period. Estimated organ absorbed doses are shown in Table 5. The dose-critical organ is thyroid, with dose estimates of 0.26 and 0.36 mSv/MBq in males and females, respectively. The prominent excretion through the bladder resulted in moderately high doses to the bladder wall, with doses depending on voiding frequency. Effective doses are shown in Table 6. Effective dose was higher in females (0.065 mSv/MBq) relative to males (0.036 mSv/MBq).

TABLE-US-00004 TABLE 4 Organ residence times of .sup.18F-TFB in healthy participants Residence Time Residence Time Organ Males (min) Females (min) Bone 4.6 ± 1.3 3.1 ± 0.3 Brain 1.2 ± 0.4 1.3 ± 0.2 Breast — 2.8 ± 0.9 Gallbladder 0.06 ± 0.03 0.09 ± 0.04 Intestines 5.7 ± 1.9 13 ± 7  Kidney 4.2 ± 1.2 3.9 ± 0.8 Liver 8.3 ± 3.9 10 ± 2  Lung 2.1 ± 0.7 2.4 ± 0.2 Muscle 36 ± 14 26 ± 8  Myocardium 2.1 ± 0.6 1.8 ± 0.3 Pancreas 0.7 ± 0.3 0.58 ± 0.08 Parotid 1.7 ± 1.1 3.3 ± 1.2 Spleen 1.5 ± 0.4 1.6 ± 0.2 Stomach 11 ± 5  24 ± 12 Thyroid 2.0 ± 0.7 2.3 ± 0.9 Bladder 17 ± 2  19 ± 4  Values arc mean ± SEM (n = 4)

TABLE-US-00005 TABLE 5 Estimated absorbed radiation dose for .sup.18F-TFB (mSv/MBq) Dose (mSv/MBq) Organ Males Females Adrenals 0.008 0.012 Brain 0.004 0.005 Breasts 0.002 0.028 Gallbladder Wall 0.012 0.022 Lower Large Intestine Wall 0.009 0.015 Small Intestine Wall 0.027 0.066 Stomach Wall 0.076 0.184 Upper Large Intestine Wall 0.045 0.109 Heart Wall 0.024 0.030 Kidneys 0.049 0.052 Liver 0.021 0.033 Lungs 0.009 0.014 Muscle 0.008 0.011 Ovaries — 0.020 Pancreas 0.034 0.043 Red Marrow 0.005 0.008 Osteogenic Cells 0.008 0.009 Skin 0.003 0.004 Spleen 0.033 0.047 Testes 0.005 — Thymus 0.004 0.005 Thyroid 0.26  0.36 Urinary Bladder Wall 0.14  0.22 Uterus — 0.022 Total Body 0.008 0.011

TABLE-US-00006 TABLE 6 Effective dose for .sup.18F-TFB in healthy participants Males Females Effective Dose (mSv/MBq) 0.036 0.065 .sup.18F-TFB Safety data

[0125] Vital signs (heart rate, diastolic and systolic blood pressures, and respiratory rate) were monitored before .sup.18F-TFB administration and throughout the PET/CT imaging period. No significant changes in the vital signs were found after .sup.18F-TFB administration (data not shown). Likewise, a panel of clinical laboratory blood tests was measured to assess for effects of .sup.18F-TFB administration on blood chemistries, including electrolytes, and liver and kidney functional tests (Supplemental data not shown). No significant changes were observed in the clinical laboratory test values for the samples acquired after .sup.18F-TFB administration relative to baseline.

Discussion

[0126] This Example evaluated the pharmacokinetics, biodistribution and radiation dosimetry of high specific radioactivity .sup.18F-TFB in eight healthy human participants. The tracer was well-tolerated and no adverse effects were noted. hNIS is known to be highly expressed in certain tissues (thyroid, breast, stomach and salivary glands) as well as hNIS-transfected tissues. Thus, non-invasive PET imaging of hNIS activity could be used to facilitate the treatment of thyroid and breast cancer and gene therapies that employ hNIS as a reporter gene. In principle, the .sup.18F-TFB PET method may also enable quantitative estimation of hNIS activity in tissues. Therefore, it may be useful to monitor changes over time for understanding the progression of disease and serial assessments of therapy response.

[0127] Since only high specific radioactivity .sup.18F-TFB was administered in this study, we did not explore the effects of specific radioactivity over a broader range. However, in our previous preclinical study with NIS-transfected C6 glioma xenografts in mice we showed that as specific radioactivity was decreased such that TFB administration levels exceeded ˜0.5 mg/kg, there was decreases seen in both thyroid and tumor uptake. Since thyroid uptake levels in the healthy participants in this study were very high, it is inferred that the specific radioactivity levels were sufficient to avoid any saturation effects do to administered TFB mass.

[0128] The regional distribution of .sup.18F-TFB in healthy participants was found to be consistent with known hNIS expression levels throughout the body tissues. The slow accumulation of .sup.18F-radioactivity seen in SUV values between the 2 and 3.5 h imaging time points could be evidence of a minor degree of radiotracer defluorination, but since routine .sup.18F-TFB PET images will likely be acquired in the 1-2 h post-injection period, the impact of this accumulation is of minor significance. Indeed, bone uptake was not qualitatively remarkable in either the 2 or 3.5 h images. Overall, the biodistribution data confirm .sup.18F-TFB to be an excellent iodide analog radiotracer with excellent in vivo stability.

[0129] The estimated radiation doses were higher in thyroid, urinary bladder wall, lower large Intestine wall, small intestine wall, upper large intestine wall, heart wall, kidneys, liver, pancreas, and spleen, but on par with other .sup.18F-labeled radiopharmaceuticals and appropriate for clinical use. Further decrease in bladder wall doses can be realized with good hydration and more frequent voiding of the bladder. Estimated effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females. Our data on the biodistribution and dosimetry estimates for .sup.18F-TFB are in general agreement with the results very recently published O'Doherty et al. (11) in five patients with thyroid cancer. In that study, 2 male and 3 female subjects were studied and the results from both genders were pooled. The specific radioactivity of their .sup.18F-TFB preparations (24±13 MBq/μg) was similar to the specific radioactivity obtained in this study.

Conclusion

[0130] The pharmacokinetics and biodistribution of high-specific activity .sup.18F-TFB in healthy human participants support its use as an iodide analog radiotracer for evaluation of thyroid and breast cancers and monitoring of gene therapies that employ the hNIS reporter gene. The radiation dosimetry estimates are on par with other .sup.8F-labeled radiopharmaceuticals with prominent renal excretion (e.g. .sup.18F-FDG) and are acceptable for clinical imaging purposes.

REFERENCES FROM EXAMPLE 2

[0131] 1. Chung J K. Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med 2002; 43:1188-1200. [0132] 2. Penheiter A R, Russell S J, and Carlson S K. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther. 2012; 12:33-47. [0133] 3. Ahn B-C. Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and Back. Theranostics. 2012; 2:392-402. [0134] 4. Dai O, Levy O, and Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996; 379:458-460. [0135] 5. Eskandari S, Loo D D F, Dai G, Levy O, Wright E M, and Carrasco N. Thyroid Na+/I− Symporter Mechanism, Stoichiometry, and Specificity. J Biol Chem. 1997; 272:27230-27238. [0136] 6. Miller A and Russell S J. The use of the NIS reporter gene for optimizing oncolytic virotherapy. Expert Opin on Biol Ther. 2016; 16:15-32. [0137] 7. Jauregui-Osoro M, Sunassee K, Weeks A J, Berry D J, Paul R L, Cleij M, et al. Synthesis and biological evaluation of F-18 tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2010; 37:2108-2116. [0138] 8. Weeks A J, Jauregui-Osoro M, Cleij M, Blower J E, Ballinger J R, and Blower P J. Evaluation of F-18-tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT16, expressing hNIS. Nucl Med Comm. 2011; 32:98-105. [0139] 9. Marti-Climent J M, Collantes M, Jauregui-Osoro M, Quincoces G, Prieto E, Bilbao I, et al. Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand F-18-tetrafluoroborate. EJNMMI Research. 2015; 5:70. [0140] 10. Youn H, Jeong J M, and Chung J-K. A new PET probe, F-18-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine. Eur J Nucl Med Mol Imaging. 2010; 37:2105-2107. [0141] 11. O'Doherty J, Jauregui-Osoro M, Brothwood T, Szyszko T, Marsden P, O'Doherty M, Cook G, Blower P, Lewington V. .sup.18F-tetrafluoroborate (.sup.18F-TFB), a PET probe for imaging sodium-iodide symporter expression: Whole-body biodistribution, safety and radiation dosimetry in thyroid cancer patients. J Nucl Med. 2017 pii: jnumed.117.192252. doi: 10.2967/jnumed.117.192252. [Epub ahead of print] [0142] 12. Jiang H L, Bansal A, Pandey M K, Peng K W, Suksanpaisan L, Russell S J, et al. Synthesis of F-18-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model. J Nucl Med 2016; 57:1454-1459. [0143] 13. Khoshnevisan A, Jauregui-Osoro M, Shaw K, Torres J B, Young J D, Ramakrishnan N K, et al. F-18 tetrafluoroborate as a PET tracer for the sodium/iodide symporter: the importance of specific activity. EJNMMI Research. 2016; 6:34.

[0144] It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and examples, the invention is not necessarily so limited, and that numerous other embodiments, examples, uses, modifications and departures from the embodiments, examples and uses are intended to be encompassed by the claims attached hereto.